- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
John Theurer Cancer Center, Hackensack University Medical Center | Strategic Alliance Partners
ABOUT HACKENSACK UNIVERSITY MEDICAL CENTER
Hackensack University Medical Center, a 803-bed nonprofit teaching and research hospital, was Bergen County’s first hospital founded in 1888. It was also the first hospital in New Jersey and second in the nation to become a Magnet®-recognized hospital for nursing excellence, receiving its sixth consecutive designation from the American Nurses Credentialing Center. The academic flagship of the Hackensack Meridian Health network, Hackensack University Medical Center is Nationally-Ranked by U.S. News & World Report 2022-2023 in four specialties, more than any other hospital in New Jersey. The hospital is home to the state's only nationally-ranked Urology and Neurology & Neurosurgery programs, as well as the best Cardiology & Heart Surgery program. It also offers patients nationally-ranked Orthopedic care and one of the state’s premier Cancer Centers (John Theurer Cancer Center at Hackensack University Medical Center). Hackensack University Medical Center also ranked as High-Performing in conditions such as Acute Kidney Failure, Heart Attack (AMI), Heart Failure, Pneumonia, chronic obstructive pulmonary disease (COPD), Diabetes and Stroke. As well as High Performing in procedures like Aortic Valve Surgery, Heart Bypass Surgery (CABG), Colon Cancer Surgery, Lung Cancer Surgery, Prostate Cancer Surgery, Hip Replacement and Knee Replacement. Named to Newsweek’s World’s Best Hospitals 2023 list, Hackensack University Medical Center is also the recipient of the 2023 Patient Safety Excellence Award™ by Healthgrades as well as an “A” Hospital Safety Grade from The Leapfrog Group. This award-winning care is provided on a campus that is home to facilities such as the Heart & Vascular Hospital; and the Sarkis and Siran Gabrellian Women’s and Children’s Pavilion, which houses the Donna A. Sanzari Women’s Hospital and the Joseph M. Sanzari Children’s Hospital, ranked #1 in the state and top 20 in the Mid-Atlantic Region in the U.S. News & World Report’s 2022-23 Best Children’s Hospital Report. Additionally, the children’s nephrology program ranks in the top 50 in the United States. Hackensack University Medical Center is also home to the Deirdre Imus Environmental Health Center and is listed on the Green Guide’s list of Top 10 Green Hospitals in the U.S. Our comprehensive clinical research portfolio includes studies focused on precision medicine, translational medicine, immunotherapy, cell therapy, and vaccine development. The hospital has embarked on the largest healthcare expansion project ever approved by the state: Construction of the Helena Theurer Pavilion, a 530,000-sq.-ft., nine-story building, which began in 2019. A $714.2 million endeavor, the pavilion is one the largest healthcare capital projects in New Jersey and will house 24 state-of-the-art operating rooms with intraoperative MRI capability, 50 ICU beds, and 175 medical/surgical beds including a 50 room Musculoskeletal Institute.
Latest from John Theurer Cancer Center, Hackensack University Medical Center
Groundbreaking Grant to John Theurer Cancer Center Will Establish the Hennessy Institute for Cancer Prevention and Applied Molecular Medicine
March 02, 2023
Article
The family of Mike and Patti Hennessy made a transformational gift in their memory to establish the Hennessy Institute for Cancer Prevention and Applied Molecular Medicine.
Adding AI Analysis to Targeted Transcriptome Represents Potential Aid for Differential Diagnosis
March 01, 2023
Article
As artificial intelligence in cancer care continues to be better understood and refined, the number of potential clinical applications is rapidly expanding.
Resistance Mutations Present an Ongoing Challenge in Aggressive Hematologic Malignancies
February 28, 2023
Article
With acquired resistance patterns emerging for nearly every agent, hematologic experts are looking closely at sequencing patterns, but more work needs to be done in aggressive malignancies in which mutations associated with resistance may be present before therapy even begins.
FDA Approval Insights: Pirtobrutinib in MCL
February 27, 2023
Podcast
Dr Leslie discusses the FDA approval of pirtobrutinib in patients with MCL previously treated with a BTK inhibitor, key efficacy and safety findings from the BRUIN trial, and potential treatment sequencing strategies in patients with resistance to covalent BTK inhibitors.
Dr. Goy on Durable Responses With Brexu-cel in the ZUMA-2 Trial in MCL
February 13, 2023
Video
Andre H. Goy, MD, discusses key findings from an assessment of durable responses in the phase 2 ZUMA-2 trial in relapsed/refractory mantle cell lymphoma.
Dr. Siegel on the Importance of Investigating Ide-cel in Multiple Myeloma
February 07, 2023
Video
David Siegel, MD, PhD, discusses the importance of investigating idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.
Dr. Siegel on Updated Results From the KarMMA-2 Trial in R/R Multiple Myeloma
February 02, 2023
Video
David Siegel, MD, discusses the significance of updated data from cohort 2C of the phase 2 KarMMa-2 trial in multiple myeloma.
Ide-cel Elicits Durable Responses in High-risk Myeloma After Inadequate ASCT Response
January 24, 2023
Article
David Siegel, MD, PhD, discusses the evaluation of idecabtagene vicleucel in cohort 2C of the KarMMa-2 trial and what these data could mean for this population and others with multiple myeloma.
Brexu-cel Elicits Durable Responses in High-Risk Relapsed/Refractory MCL
January 13, 2023
Article
Treatment with brexucabtagene autoleucel produced ongoing responses in patients with mantle cell lymphoma with high-risk disease characteristics, including those with a lower ECOG performance score and tumor burden and less frequent prior use of bridging or platinum therapy.
Dr. Leslie on the 3-Year Follow-Up of the ZUMA-5 Trial in R/R iNHL
December 19, 2022
Video
Lori A. Leslie, MD, discusses the 3-year follow-up data of the phase 2 ZUMA-5 trial in patients with relapsed/refractory indolent non-Hodgkin lymphoma.
Hackensack Meridian Health Appoints Internationally Renowned Thoracic Surgeon Faiz Y. Bhora, MD, FACS, as Central Region Chair of Surgery
November 17, 2022
Article
Expert in minimally invasive and robotic surgery will expand access to new technology and advancesurgical research in Central New Jersey.
Dr. Goy on the Clinical Implications of Treating Indolent MCL
November 15, 2022
Video
Andre H. Goy, MD, discusses the clinical implications of treating indolent mantle cell lymphoma.
DREAMSeq Trial Clarifies Treatment Sequencing in BRAF V600–Mutant Melanoma
November 08, 2022
Article
Immunotherapy followed by targeted therapy has emerged as the new standard of care for patients with melanoma with BRAF V600 mutations.
Dr. Pecora on Key Efficacy Findings from the DREAMSEQ Trial in BRAF-Mutated Melanoma
November 03, 2022
Video
Andrew L. Pecora, MD, discusses the key efficacy findings from the phase 3 DREAMSEQ trial in BRAF-mutated melanoma.
Dr. Goy on Discrepancies in Clinical Trial vs Real-World MCL Treatment
October 17, 2022
Video
Andre H. Goy, MD, discusses clinical trial vs real-world treatments in patients with mantle cell lymphoma.
Dr. Gutierrez on the Investigation of MK-0482 in Advanced Solid Tumors
September 16, 2022
Video
Martin E. Gutierrez, MD, discusses the investigation of MK-0482 in advanced solid tumors.
Dr. Bhatt on the Investigation of Trastuzumab Deruxtecan in HER2-Low Breast Cancer
September 16, 2022
Video
Ruchi Bhatt, DO, discusses the investigation of trastuzumab deruxtecan in HER2-low breast cancer.
Dr. Anne on the Practice-Changing Data of DESTINY-Breast04 in HER2-Low Breast Cancer
September 16, 2022
Video
Madhurima Anne, MD, discusses the practice-changing data of the phase 3 DESTINY-Breast04 trial in patients with HER2-low breast cancer.
Dr. Goy on Updates in Precision Medicine in Hematologic Malignancies
September 15, 2022
Video
Andre H. Goy, MD, discusses updates in precision medicine.
Dr. Ip on the Utility of Carboplatin, Pemetrexed, and Pembrolizumab in Lung Adenocarcinoma
September 15, 2022
Video
Andrew Ip, MD, discusses carboplatin, pemetrexed, and pembrolizumab as first-line therapy in recurrent/metastatic non–small cell lung cancer.